These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1801634)

  • 41. Factors in human serum promoting phagocytosis of Pseudomonas aeruginosa. I. Interaction of opsonins with the bacterium.
    Bjornson AB; Michael JG
    J Infect Dis; 1974 Nov; 130 Suppl(0):S119-26. PubMed ID: 4214223
    [No Abstract]   [Full Text] [Related]  

  • 42. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
    Bauernfeind A; Przyklenk B
    Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
    [No Abstract]   [Full Text] [Related]  

  • 43. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides.
    Pollack M; Tao M; Akiyama M; Pier GB; Koles NL
    Antibiot Chemother (1971); 1991; 44():163-71. PubMed ID: 1801635
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibodies against Pseudomonas aeruginosa in patients with bronchiectasis: helpful or harmful?
    Høiby N
    Thorax; 2001 Sep; 56(9):667-8. PubMed ID: 11514683
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.
    Thomsen K; Christophersen L; Jensen PØ; Bjarnsholt T; Moser C; Høiby N
    Hum Vaccin Immunother; 2016 Jul; 12(7):1690-9. PubMed ID: 26901841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains.
    Baltimore RS; Mitchell M
    J Infect Dis; 1980 Feb; 141(2):238-47. PubMed ID: 6444976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.
    Brett MM; Ghoneim AT; Littlewood JM
    Arch Dis Child; 1990 Mar; 65(3):259-63. PubMed ID: 2110441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.
    Brett MM; Simmonds EJ; Ghoneim AT; Littlewood JM
    Arch Dis Child; 1992 Sep; 67(9):1086-8. PubMed ID: 1417051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.
    Fick RB; Naegel GP; Matthay RA; Reynolds HY
    J Clin Invest; 1981 Oct; 68(4):899-914. PubMed ID: 6793632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune complexes and Pseudomonas aeruginosa antibodies in cystic fibrosis.
    Van Bever HP; Gigase PL; De Clerck LS; Bridts CH; Franckx H; Stevens WJ
    Arch Dis Child; 1988 Oct; 63(10):1222-8. PubMed ID: 3143315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients.
    Gottlieb DJ; Cryz SJ; Furer E; Que JU; Prentice HG; Duncombe AS; Brenner MK
    Blood; 1990 Dec; 76(12):2470-5. PubMed ID: 2124933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
    Cryz SJ; Fürer E; Sadoff JC; Fredeking T; Que JU; Cross AS
    J Infect Dis; 1991 May; 163(5):1055-61. PubMed ID: 1902245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.
    Zuercher AW; Imboden MA; Jampen S; Bosse D; Ulrich M; Chtioui H; Lauterburg BH; Lang AB
    Clin Exp Immunol; 2005 Nov; 142(2):381-7. PubMed ID: 16232228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of antibodies to selected antigens of Pseudomonas aeruginosa in children and young adults with cystic fibrosis.
    Gaweł J; Pogorzelski A; Działek-Smętek E; Sochań B; Ligarska R; Lącka M; Mazurek H
    Pneumonol Alergol Pol; 2014; 82(4):336-41. PubMed ID: 24964236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.
    Ames P; DesJardins D; Pier GB
    Infect Immun; 1985 Aug; 49(2):281-5. PubMed ID: 3160660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
    Pier GB
    J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey.
    Hoiby N
    Acta Pathol Microbiol Scand Suppl; 1977; (262):1-96. PubMed ID: 411327
    [No Abstract]   [Full Text] [Related]  

  • 58. Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis.
    Pennington JE
    J Infect Dis; 1974 Nov; 130 Suppl(0):S159-62. PubMed ID: 4213986
    [No Abstract]   [Full Text] [Related]  

  • 59. Antibody response to Pseudomonas aeruginosa antigens in cystic fibrosis.
    Pedersen SS; Høiby N; Shand GH; Pressler T
    Antibiot Chemother (1971); 1989; 42():130-53. PubMed ID: 2512834
    [No Abstract]   [Full Text] [Related]  

  • 60. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.